Increased risk of purge system malfunction after Impella 5.0 replacement: a case series

Oishi, Hideo; Morimoto, Ryo; Ito, Ryo; Kazama, S.; Kimura, Yuki; Araki, Takashi; Mizutani, Takashi; Kuwayama, Tasuku; Hiraiwa, Hiroaki; Kondo, Toru; Okumura, Takahiro; Mutsuga, Masato; Usui, Akihiko; Murohara, Toyoaki

doi:10.1007/s10047-022-01337-0

Cited by 3 publications

(1 citation statement)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although uncommon, device malfunction has been reported. 27 In our experience, device malfunction has been commonly associated with a malfunction of the purge system, typically a fracture within the purge solution tubing. In these instances, the Impella device must be exchanged prior to failure of the device.…”

Section: Device Malfunctionmentioning

confidence: 98%

The 10 Commandments of Microaxial Temporary Left Ventricular Assist Devices

Hess

Ziegler

Kaczorowski

2022

Innovations�(Phila)

View full text Add to dashboard Cite

Section: Device Malfunctionmentioning

confidence: 98%

The 10 Commandments of Microaxial Temporary Left Ventricular Assist Devices

Hess

Ziegler

Kaczorowski

2022

Innovations�(Phila)

View full text Add to dashboard Cite

Usefulness of bicarbonate-based Impella purge solution in a patient with heparin-induced thrombocytopenia: the first case report of long-term management in Japan

Nagai,

Hiraiwa,

Ito

et al. 2024

J Artif Organs

View full text Add to dashboard Cite

Percutaneous mechanical circulatory support utilizing micro-axial flow pumps, such as the Impella group of devices, has become a life-saving technique in the treatment of refractory cardiogenic shock, with ever-increasing success rates. A 30-year-old man presented with acute decompensated heart failure and a severely reduced left ventricular ejection fraction (17%). Despite initial treatment with inotropic drugs and intra-aortic balloon pump support, his hemodynamic status remained unstable. Transition to Impella CP mechanical circulatory support was made on day 6 owing to persistently low systolic blood pressure. A significant decline in platelet count prompted suspicion of heparin-induced thrombocytopenia (HIT), later confirmed by positive platelet-activated anti-platelet factor 4/heparin antibody and a 4Ts score of 6 points. Argatroban was initially used as the purge solution, but owing to complications, a switch to Impella 5.0 and a bicarbonate-based purge solution (BBPS) was performed. Despite additional veno-arterial extracorporeal membrane oxygenation support on day 24, the patient, aiming for ventricular assist device treatment and heart transplantation, died from infection and multiple organ failure. Remarkably, the Impella CP continued functioning normally until the patient’s demise, indicating stable Impella pump performance using BBPS. This case highlights the usefulness of BBPS as an alternative to conventional Impella heparin purge solution when HIT occurs.

show abstract

The Role of Ventricular Assist Devices in Patients With Heart Failure Due to Dilated Cardiomyopathy: A Systematic Review

McBenedict,

Hauwanga,

Amadi

et al. 2024

Cureus

View full text Add to dashboard Cite

Dilated cardiomyopathy (DCM) is a prevalent heart muscle disease characterized by ventricular dilation and systolic dysfunction, leading to severe heart failure (HF) and often requiring heart transplantation (HTx). This systematic review aimed to synthesize information regarding the role of ventricular assist devices (VADs) in managing HF patients due to DCM. A comprehensive search was conducted across PubMed, Embase, Scopus, Web of Science, and Cochrane databases for studies published between 2014 and 2024. Inclusion criteria were studies involving adult patients with HF due to DCM treated with VADs. Exclusion criteria included non-human studies, pediatric populations, and non-peer-reviewed articles. Thirty-one studies met the inclusion criteria. The included studies demonstrated that the use of VADs in patients with DCM resulted in significant improvements in left ventricular ejection fraction (LVEF), myocardial fibrosis reduction, and reverse ventricular remodeling. Studies reported enhanced survival rates, reduced symptoms, and better quality of life. VADs served as a critical bridge to HTx and, in some cases, as long-term destination therapy. However, complications such as thrombus formation, anemia, and kidney failure were noted, emphasizing the need for vigilant monitoring and management. Continuous advancements in VAD technology and patient management protocols were found to be essential for optimizing outcomes. We conclude that VADs play a crucial role in managing advanced HF due to DCM by providing mechanical circulatory support, improving cardiac function, and enhancing patient survival and quality of life. Despite associated complications, VADs are invaluable for patients with severe HF, offering both immediate and long-term therapeutic benefits. Future research should focus on minimizing complications and further improving VAD technology to enhance patient outcomes.

show abstract

Increased risk of purge system malfunction after Impella 5.0 replacement: a case series

Cited by 3 publications

References 8 publications

The 10 Commandments of Microaxial Temporary Left Ventricular Assist Devices

The 10 Commandments of Microaxial Temporary Left Ventricular Assist Devices

Usefulness of bicarbonate-based Impella purge solution in a patient with heparin-induced thrombocytopenia: the first case report of long-term management in Japan

The Role of Ventricular Assist Devices in Patients With Heart Failure Due to Dilated Cardiomyopathy: A Systematic Review

Contact Info

Product

Resources

About